Amgen Downgraded as Novartis Clinical Trial Failure Clouds Drug Outlook

Key Facts

In a move reflecting the high sensitivity of the biotech sector to clinical outcomes, Amgen faced significant pressure following a major setback for a key industry rival. BMO Capital downgraded Amgen stock from Outperform to Market Perform after Novartis' experimental drug, pelacarsen, failed to meet its primary goal in a late-stage Phase III study. According to reports, Amgen shares fell 5% in after-hours trading as investors grew cautious about the prospects for its own rival drug, olpasiran, which targets the same therapeutic market.

This rating shift highlights the increased risk profile for the Lp(a) drug class, which both companies had positioned for a multi-billion dollar market. Per analyst data, Amgen had previously enjoyed a year-to-date rally of 36.30%, significantly outperforming the broader industry's 11.10% rise. However, the clinical failure at Novartis has introduced uncertainty regarding the efficacy of similar treatments, prompting a re-evaluation of Amgen's growth premium compared to its peers.

Regarding market levels, authoritative price data is currently unavailable for the latest session; however, the directional trend remains bearish following the after-hours drop on September 8, 2026. Traders should watch for any clarifying statements from Amgen management regarding their clinical pipeline. Additionally, broader market sentiment may be influenced by upcoming US economic data, though no specific healthcare sector catalysts are listed in the immediate calendar.